AbbVie Gets Positive EU Opinion on Leukemia Treatment
By Matt Grossman
AbbVie Inc. said Friday it received a positive opinion from the
European Medicines Agency's Committee for Medicinal Products for
Human Use regarding its Venclyxto treatment for people with acute
The opinion covers the use of Venclyxto combined with
hypomethylating agents to treat adults with newly diagnosed AML who
are ineligible for chemotherapy. The body's opinion is a scientific
recommendation that will feed into the European Commission's
decision on whether to grant the therapy marketing
The EC is expected to give its final decision on the therapy in
the first half of this year, AbbVie said.
AML is the most common type of acute leukemia, with about
160,000 people in the world currently living with the disease,
North Chicago, Ill.-based AbbVie said.
Write to Matt Grossman at email@example.com
(END) Dow Jones Newswires
April 23, 2021 08:45 ET (12:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.